Viewing Study NCT07166367


Ignite Creation Date: 2025-12-25 @ 12:32 AM
Ignite Modification Date: 2025-12-25 @ 10:39 PM
Study NCT ID: NCT07166367
Status: TERMINATED
Last Update Posted: 2025-09-10
First Post: 2025-09-03
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
Sponsor: National Cancer Centre, Singapore
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module